Rolling Start-Up Key In Global Observational Cohort Study For Patients With Psoriasis

UBC was selected by a large biopharmaceutical company to manage a 5 year (2 year enrollment, 3 year follow-up) observational cohort study for patients with moderate-severe psoriasis who are initiating or switching to a new biologic. The global study spanned 268 sites across 23 countries in North America, Latin America, Europe, Asia, Middle East, and Australia and included 3,200 patients in routine care setting. The observational study was designed to compare treatment effectiveness in three patient cohorts, each prescribed a specific biologic treatment in clinical practice, as well as to compare improvement in patientreported outcomes (PRO) across treatments.